There is no cure for diabetes-related neuropathy. However, you can control it with medications, therapy, and tighter blood sugar control. Diabetes-related neuropathy is nerve damage that affects people with diabetes. The most common type is peripheral neuropathy, which often affects the feet.
In a recent issue of JCI, the same group of researchers advanced their observations by reporting on the effect of VEGF gene transfer on experimental diabetic neuropathy (1.Using a design similar to that of the previous report, they studied the functions of peripheral nerves in diabetic rats induced by streptozotocin). The large nerve fibers were tested by measuring nerve conduction velocities, while the function of the small fibers was evaluated by testing the movement of the tail in response to a harmful thermal stimulus. Surprisingly, the transfer of the VEGF gene 12 weeks after the induction of diabetes completely restored the nerve function anomalies studied. both in large and small fibers.
In addition, VEGF restored nerve blood flow and the number of nerve vessels to the levels seen in non-diabetic animals, indicating that VEGF exerts its beneficial effects by promoting angiogenesis in peripheral nerves. The authors observed similar effects in alloxan-induced diabetic rats, indicating that these effects are not specific to a single animal model. While it is tempting to speculate that the observed improvement in nerve electrophysiology must be the basis for a considerable normalization of nerve pathology, this hypothesis has not yet been proven by histological analysis. The bottom line is that, unless neuropathy is in its initial phase, the condition is in largely irreversible measure.
That said, since neuropathy is progressive, there are ways to stop the condition, contain the damage, and keep you more comfortable. Sometimes neuropathy can improve over time if the cause is treated, but in some people the damage may be permanent or worsen over time. Often, treatment for neuropathy focuses on symptoms, not on the nerve damage itself. Diabetes mellitus is a common and serious complication of diabetes mellitus, causing significant morbidity and reduced quality of life.
Despite its prevalence, there are currently no specific therapeutic strategies that can reverse diabetic nerve damage once it has occurred. The early signs of neurological disease are often subtle and unspecific, which can delay diagnosis and progress to irreversible stages of nerve damage 101. Therefore, proactive prevention and early intervention are crucial to mitigate the impact of this condition (fig. Could the reversion of diabetes-related neuropathy be another benefit of bariatric surgery? Evidence suggests that yes. However, we need more studies, including clinical trials, that compare the results of people from different groups. Cytokines and chemokines at the crossroads of neuroinflammation, neurodegeneration and neuropathic pain.
Cav3.2 T-type calcium channels in peripheral sensory neurons are important for reversing mibefradil-induced hyperalgesia and allodynia in rats with painful diabetic neuropathy. Although diabetes-related neuropathy cannot be reversed or cured, it is possible to control the complication of diabetes and prevent it from worsening. Painful and painless neuropathies are distinct entities and, to a large extent, undiagnosed in individuals who participate in an educational initiative (PROTECT study). Diabetic neuropathies comprise a diverse group of clinical syndromes, generally classified according to the pattern of neurological involvement.
Acetyl-L-carnitine (ALC) facilitates the transport of fatty acids to mitochondria, improving cellular energy production, and has neuroprotective properties that alleviate neuropathic pain, improve sensory function and improve nerve conduction. The need for simple tests to detect diabetic peripheral neuropathy in patients with type 2 diabetes mellitus without neuropathic symptoms in clinical practice. Therefore, VEGF may act to reverse the catabolic phase locally, by increasing blood flow to the affected limb, instead of reversing conditions that are specifically related to the development of diabetic neuropathy in humans. ARA 290, a non-erythropoietic peptide designed from erythropoietin, improves metabolic control and neuropathic symptoms in patients with type 2 diabetes. But is there hope of reversing diabetic neuropathy, or is it a lifelong problem? Let's explore what diabetic neuropathy is, if it can be reversed, and what are the best strategies to control and slow its progression.
Randomized, double-blind, placebo-controlled and active study on the T-type calcium channel blocker ABT-639 in patients with diabetic peripheral neuropathic pain.
